BioLife Solutions (BLFS) shares have surged more than 80% in early trading today after the company announced that it closed a 10-year supply agreement with Kite Pharma (KITE) or its clinical grade freeze media for cells and tissues, CryoStor, which is embedded in Kite's manufacturing process for lead product candidate KTE-C19, a CAR-T cell therapy under development for the treatment of a range of cancers.